Ceribell, Inc. (CBLL): Results of Operations and Financial Condition
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor
How this was made
The 30-second read
Why it matters
Key trading inputs are the raised FY2026 revenue guidance, Q2 revenue and margin performance, and incremental financing (up to $60M committed) alongside FDA 510(k) clearances and NTAP reimbursement effective Oct 1, 2026.
Market read
Traders can update models immediately using the raised FY2026 revenue range and assess funding runway via the new credit facility, while monitoring margin quality given tariff-refund impact.
What to watch
Operating expenses rose 37% and the company highlights legal costs tied to an IP infringement suit, which could pressure future profitability despite revenue growth.
Background
This is Ceribell’s SEC Form 8-K (Item 2.02) with an attached earnings release for Q2 2026 ended June 30, 2026.
Ticker impact
Ceribell reported Q2 2026 revenue of $28.1M (+33% YoY), raised FY2026 revenue guidance to $114M-$117M, and secured up to $60M in new credit.
Likely positive bias for the next session and into guidance digestion, with volatility around margin and operating expense growth details.
Guidance raise ($114M-$117M) and committed capital ($60M) are direct, time-sensitive catalysts; FDA clearances and NTAP timing (effective Oct 1, 2026) add incremental demand visibility.
Market effects
Supports sentiment for EEG/neurology diagnostic device adoption and reimbursement pathways (NTAP) within medical technology.
Limited direct regional spillover; mostly US reimbursement and FDA clearance driven.
Manufacturing in Vietnam/China is referenced, but the disclosed catalysts are US regulatory and reimbursement.
Counterpoint
Gross margin is very high but includes a one-time tariff refund benefit, so underlying margin durability may be less strong than the headline suggests.
Key entities
- companyCeribell, Inc.
Nasdaq-listed medical technology company focused on EEG-based diagnosis and monitoring of neurological conditions.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Awarded NTAP for Ceribell’s delirium monitoring solution effective Oct 1, 2026.
- regulatorU.S. Food and Drug Administration (FDA)
Granted multiple 510(k) clearances for Ceribell algorithms and next-generation hardware components.
